ProShares Ultra NASDAQ Biotechnology
27 hedge funds and large institutions have $19.7M invested in ProShares Ultra NASDAQ Biotechnology in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 6 closing their positions.
178% more capital invested
Capital invested by funds: $7.07M → $19.7M (+$12.6M)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
4% more funds holding
Funds holding: 26 → 27 (+1)
3.52% more ownership
Funds ownership: 5.77% → 9.29% (+3.5%)
25% less call options, than puts
Call options by funds: $8.44M | Put options by funds: $11.2M
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$7.68M |
| 2 |
CIC
Chase Investment Counsel
Charlottesville,
Virginia
|
+$2.29M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.16M |
| 4 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
+$408K |
| 5 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
+$259K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$1.79M |
| 2 |
SBIA
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
|
-$694K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$430K |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$261K |
| 5 |
Morgan Stanley
New York
|
-$124K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CG
26
Cutler Group
San Francisco,
California
| $9K | +$8.05K | +126 | New |
|
|
SL
27
Savior LLC
Wellesley Hills,
Massachusetts
| $1K | +$639 | +10 | New |
|
|
HF
28
HRT Financial
New York
| – | -$1.79M | -38,720 | Closed |
|
|
SBIA
29
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
| – | -$694K | -15,000 | Closed |
|
|
TI
30
Trexquant Investment
Stamford,
Connecticut
| – | -$261K | -5,647 | Closed |
|
31
Bank of America
Charlotte,
North Carolina
| – | -$79K | -1,700 | Closed |
|
32
UBS Group
Zurich,
Switzerland
| – | -$32K | -696 | Closed |
|
|
CBT
33
Capital Bank & Trust
Irvine,
California
| – | -$11K | -232 | Closed |
|
BIB Hedge Fund Activity: Q2 2020 in Review
27 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q2 2020, worth a combined $19.7M — up 178% from $7.07M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BIB positions and 6 closed out — a net gain of 1 holder — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Geneos Wealth Management, adding an estimated $7.68M. The largest seller was HRT Financial, exiting entirely with an estimated $1.79M sold.
- 27 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q2 2020, up from 26 in Q1 2020.
- Funds reported $19.7M of ProShares Ultra NASDAQ Biotechnology stock for Q2 2020, up 178% quarter-over-quarter.
- 7 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q2 2020 and 6 closed out, a net change of +1 holder.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q2 2020 was Geneos Wealth Management, an estimated $7.68M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q2 2020 was HRT Financial, an estimated $1.79M sold.
Based on aggregated 13F filings for Q2 2020.